Riskpilot← Back to searchSign inGet full accessSiMSen Diagnostics AB
ABActiveOrg 5592385206MölndalResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20201-4 employees
Revenue 2024
SEK 778K
-12% vs 2023
EBITDA margin
-1012.5%
-116% vs 2023
Equity ratio
-7.7%
Financial strength
Net profit 2024
SEK -8M
-121% vs 2023
| Revenue | SEK 778K | -12% |
| EBITDA | SEK -7,9M | -116% |
| Net profit | SEK -8M | -121% |
| Total assets | SEK 4M | -57% |
| Equity | SEK -305K | -104% |
| Employees | — | — |
Legal name
SiMSen Diagnostics AB
Org number
5592385206
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24 januari 2020
Share capital
SEK 34 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna eller en av dem i förening med suppleanten Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva utveckling och kommersialisering av molekylär diagnostik och därmed förenlig verksamhet.
Address
Mölndal
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 537 | 887 | 778 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −28 | −418 | −1 228 | −3 648 | −7 877 |
| Depreciation & amort. | −0 | −7 | −40 | −111 | −164 |
| EBIT | −28 | −425 | −1 268 | −3 759 | −8 041 |
| Net financials | — | — | — | 145 | 70 |
| Profit before tax | −28 | −425 | −1 268 | −3 614 | −7 970 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −28 | −425 | −1 268 | −3 614 | −7 970 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 852 | 2 935 | 1 853 | 9 163 | 3 952 |
| Equity | 844 | 2 694 | 1 426 | 7 666 | −305 |
| Long-term debt | 0 | 0 | 0 | 400 | 356 |
| Short-term debt | 8 | 241 | 426 | 1 097 | 3 901 |
| Total debt | 8 | 241 | 426 | 1 497 | 4 257 |
EBITDA margin
-1012.5%
This company
15.8%
Market median
-6508% vs market
20202024
Equity ratio
-7.7%
This company
38.2%
Market median
-120% vs market
20202024
Return on equity
-797000000.0%
This company
18.4%
Market median
-4331521839% vs market
20202024
Net profit margin
-1024.4%
This company
8.1%
Market median
-12747% vs market
20202024
Asset turnover
0.20×
This company
1.12×
Market median
-82% vs market
20202024
Debt / equity
13.96×
This company
0.62×
Market median
-2152% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
FP Chief Auditor | Chief Auditor | 2020 | — | — |
BG Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
PC Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2025 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Deputy Board Member | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SiMSen Diagnostics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Filip Patrik Laurin | Chief Auditor | 0 companies |
| Bengt Gustav Emanuel Johansson | Chief Executive Officer | 0 companies |
| Pontus Christian Georg Rehn | Chief Executive Officer | 0 companies |
| Artur Bernardino Aira | Board of Directors | 0 companies |
| Jan Erik Gustav Smith | Board of Directors | 0 companies |
| Mikael Kubista | Board of Directors | 0 companies |
| Hanna Maria Mann | Board of Directors | 0 companies |
| M H Charlotte Wiberg Larsson | Chairman | 0 companies |
| Inger Helena Ströberg | Deputy Board Member | 0 companies |
| Bo Torsten Nilsson | Board of Directors | 0 companies |
| Sven Mathias Hallin | Deputy Board Member | 0 companies |
| Nils Olov Nilsson | Board of Directors | 0 companies |
| Christina Maria Yvonne Hall | Board of Directors | 0 companies |
| Dominique Laurence Barbara Gouty | Board of Directors | 0 companies |
| Daniel Johan Poté | Chairman | 0 companies |
| Bengt Anders Waas | Chairman | 0 companies |
| Anders Torbjörn Ståhlberg | Board of Directors | 0 companies |
| Anette Helena Lundquist | Deputy Board Member | 0 companies |
| Jan Roland Pilebjer | Chairman | 0 companies |
| Tony Edward Godrey | Board of Directors | 0 companies |
| Peter Jonas Michael Carlborg | Deputy Board Member | 0 companies |
| Erik Johan Brobjer | Board of Directors | 0 companies |
| Bo Torsten Patrik Nilsson | Deputy Board Member | 0 companies |